Patent · US Active

Compounds for treating prostate cancer

US10882834B2 · kind B2 · utility

1Cited by
7References
15Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 18, 2014
Grant dateJan 5, 2021
Priority date
Expiry dateSep 18, 2034

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D413/12
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: R20—(Z)b—(Y)c—(R21)a—X—R22—R23 wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; Z is alkanediyl, substituted alkanediyl, cycloalkanediyl, or substituted cycloalkanediyl; Y is S, O, or NR10, wherein R10 is H or alkyl; R21 is alkanediyl, substituted alkanediyl, cycloalkanediyl, substituted cycloalkanediyl, alkadienyl, substituted alkadienyl, alkatrienyl, substituted alkatrienyl; X is —C(=0)- or —S(=0)(=0)-; R22 is a moiety that includes at least one divalent amino radical; R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; a is 0 or 1; b is 0 or 1; and c is 0 or 1; provi…

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.